Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...

Ethan Smith, therapy area director Oncology, Norstella, explores how antibody–drug conjugates are reshaping oncology, highlighting emerging challenges around treatment sequencing, safety management ...

Antibody-drug conjugates (ADCs) were associated with a higher risk for all-grade adverse events (AEs) in metastatic breast cancer than standard therapy, according to a meta-analysis. However, these ...

The field of oncology has seen transformative advancements with the development of antibody-drug conjugates (ADCs), which are rapidly revolutionizing the treatment of several cancer types, including ...